FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma

FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma

Source: 
CP Wire
snippet: 

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma who have received one or two prior lines of therapy, including at least one vascular endothelial growth factor tyrosine kinase inhibitor or the combination of nivolumab and ipilimumab.